OTLK
Outlook Therapeutics, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
0.65
▼ 0.02 (3.22%)
MARKET · —
Price
Open
0.69
Prev close
0.68
Day high
0.71
Day low
0.64
Volume
11.33M
Market cap
—
P/E (TTM)
—
52W range
0.16 – 3.39
Trailing performance
Returnvs SPY
1W
-14.42%
-13.1%
1M
-50.98%
-54.7%
3M
+94.29%
+91.2%
6M
+56.66%
+45.6%
YTD
-59.05%
-71.3%
1Y
-72.93%
-92.9%
3Y
-97.62%
-171.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.84
-22.18% from price
SMA 20
0.91
-29.26% from price
SMA 50
1.27
-49.20% from price
SMA 100
0.82
-20.42% from price
SMA 200
0.90
-28.11% from price
EMA 12
0.82
-20.39% from price
EMA 26
0.98
-32.94% from price
EMA 50
1.03
-36.18% from price
RSI (14)
32.2
Neutral
MACD (12,26,9)
-0.15
Hist -0.03
ATR (14)
0.12
18.86% of price
Realised vol 30D
146.0%
Annualised
Bollinger upper
1.24
20, 2σ
Bollinger lower
0.59
20, 2σ
50 / 200 cross
Golden
1.27 vs 0.90
Trend bias
Below 200
-28.11%
Risk profile
Beta vs SPY
0.94
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
146.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-93.3%
Peak to trough
Max drawdown 5Y
-99.6%
Peak to trough
ATR 14
0.12
18.86% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
BC-Most Active Stocks
Associated Press · 5d ago
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Zacks · 5d ago
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing
MT Newswires · 6d ago
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
Simply Wall St. · 8d ago
Oncobiologics Q3 Earnings Call Highlights
MarketBeat · 8d ago
Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby · 8d ago
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Zacks · 8d ago
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
GlobeNewswire · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.